What is it about?
The formulation of indacaterol and mometasone in the easy-to-use intuitive Breezhaler shows tremendous impact. The molecules are well known - mometasone for 20 plus years in asthma treatment and indacterol for 10 plus years in difficult COPD treatment. Combined, they have a great impact than the market leader until now - Advair (Seretide outside of North America). Most importantly, this new combination can be taken just once daily in the treatment of asthma.
Featured Image
Photo by Lucrezia Carnelos on Unsplash
Why is it important?
The combination of well-established drugs with track records of safety to create a novel combination helps make better treatment options available sooner for patients. It is a great example of working smarter to improve care.
Perspectives
IRL is delighted to have been a part of this important development for Canadians with asthma.
Professor Kenneth R Chapman
University of Toronto
Read the Original
This page is a summary of: Indacaterol/Mometasone Furoate Fixed-Dose Combination Improves Lung Function and Decreases Exacerbations Compared with Salmeterol/Fluticasone in Patients with Uncontrolled Asthma: Pooled Analyses of PALLADIUM and IRIDIUM Studies, May 2020, American Thoracic Society,
DOI: 10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a3004.
You can read the full text:
Resources
Contributors
The following have contributed to this page
